Skip to main content
NCBI home page
Neuropsychiatric Disease and Treatment logoLink to Neuropsychiatric Disease and Treatment
. 2018 Dec 24;15:83–94. doi: 10.2147/NDT.S184067

Associations of BRAP polymorphisms with the risk of alcohol dependence and scores on the Alcohol Use Disorders Identification Test

Jee Wook Kim 1,2, Young Min Choe 1,2, Joong-Gon Shin 3, Byung Lae Park 4, Hyung-Doo Shin 3,4, Ihn-Geun Choi 2,5, Boung Chul Lee 2,6,✉
PMCID: PMC6309135  PMID: 30636874

Abstract

Background

Alcohol dependence (AD) is a common disorder that is influenced by genetic as well as environmental factors. A previous genome-wide association study (GWAS) of the Korean population performed by our research group identified a number of genes, including BRCA1-associated protein (BRAP) and protein arginine methyltransferase 8 (PRMT8), as novel genetic markers of AD.

Methods

The present investigation was a fine-mapping follow-up study of 459 AD and 455 non-AD subjects of Korean descent to determine the associations between BRAP and PRMT8 polymorphisms and AD. The Alcohol Use Disorders Identification Test (AUDIT) was administered to screen for the degree of AD risk in the subjects and 58 genetic variants, 5 for BRAP and 53 for PRMT8, were genotyped for subsequent association analyses.

Results

In the present case–control analysis, BRAP rs3782886 showed the most significant association signal with a risk of AD (P=1.29×10−16, Pcorr =7.74×10−16, OR =0.19). There were also significant differences in the overall and subcategory scores for the BRAP genetic variants, including rs3782886 (P=9.94×10−31, Pcorr =5.96×10−30 at rs3782886 for the overall AUDIT score). However, the genetic effects of PRMT8 polymorphisms observed in our previous GWAS were not replicated in the present study (minimum P=0.0005, Pcorr >0.05, OR =0.30 at rs4766139 in the recessive model). Furthermore, the single-nucleotide polymorphisms of PRMT8 were not associated with the overall and subcategory AUDIT scores.

Conclusion

The present findings suggest that the genetic variants of BRAP may contribute to a predisposition for an alcohol use disorder.

Keywords: alcohol dependence, AUDIT, genome-wide association study, single-nucleotide polymorphism, BRAP

Introduction

Alcohol dependence (AD) is a severe psychiatric disorder with a multifactorial etiology that includes complex gene-to-gene and gene-to-environment interactions.1–3 Adoption and twin studies conducted to clarify the effects of genes in this etiology have revealed that genetic factors comprise 50%–60% of the heritability of AD susceptibility.4,5 Additionally, adoptees are more similar to their biologic parents than their adoptive parents in terms of AD susceptibility6,7 and the higher concordance for AD susceptibility between twins is derived from shared genetic components.8 In fact, several candidate studies assessing the risk loci for AD were designed to target gene variants related to alcohol metabolism or neurobiology.9–13

Recently, a number of genome-wide association studies (GWASs) have investigated genetic markers of AD, including the genomic region of chromosome 4q22-q32, which includes alcohol dehydrogenase (ADH) cluster genes.14–17 Furthermore, a recent GWAS of a Korean AD cohort revealed that three chromosomal regions are associated with AD, including the ADH gene cluster and ALDH2, which participate in alcohol metabolism (minimum P=6.46×10−8, OR =2.73 at ADH7 rs10516441 of the ADH gene cluster and P=8.42×10−8, OR =0.22 at ALDH2 rs671). The genetic effects of the ADH gene cluster were also replicated in a Korean population (minimum P=2.63×10−21 at ADH1B rs1229984). In addition to genes related to alcohol metabolism, genes known to participate in neurodevelopment, such as BRCA1-associated protein (BRAP) and protein arginine methyltransferase 8 (PRMT8), have multiple association signals with the risk of AD (P=4.65×10−6, OR =0.31 at BRAP rs3782886 and P=1.77×10−5, OR =1.96 at PRMT8 rs876594).18 Based on the polygenic hypothesis of AD pathophysiology, it is possible that multiple genetic loci associated with neurobiologic pathways could be associated with the risk of AD. Thus, the present investigation conducted followup replication studies of our previous GWAS of a Korean cohort with AD to identify associations between the risk of AD and novel candidate genes other than those related to alcohol metabolism.

Methods

Subject recruitment and the Alcohol Use Disorders Identification Test (AUDIT)

The present study recruited 914 individuals of Korean descent from Hangang Sacred Heart, Keyo, Dasarang, KARF, and Humanity and Youth Rehabilitation Hospitals. Of these individuals, 459 were alcoholic subjects and 455 were nonalcoholic subjects; the nonalcoholic subjects were recruited from the industrial medical center of Hangang Sacred Heart Hospital. All subjects enrolled in this study underwent inpatient therapy for >30 days due to their drinking problems and the patients who comprised a subgroup in our previous study did not have major medical or comorbid psychiatric illnesses other than an alcohol-related disorder.11,19 AD was diagnosed clinically with a semi-structured interview based on the guidelines of the Diagnostic and Statistical Manual of Mental Disorders IV20 by skilled psychiatrists as well as on information provided by their caregivers; diagnostic validity was high because all subjects were hospitalized in alcohol-related hospitals. Most of the healthy controls were nondrinkers, although some were occasional light drinkers as revealed by a drinking habit questionnaire. Subjects who had first-degree relatives with major psychiatric disorders, including schizophrenia, mood disorders, and/or substance abuse disorders other than nicotine dependence, were excluded from the present analyses. The study protocol was approved by the institutional review board of each hospital. All participants provided written informed consent, and that this study was conducted in accordance with the Declaration of Helsinki.

The AUDIT was administered to screen for the degree of AD risk in the subjects.21 The AUDIT consists of ten items and is often used in Asian populations, including the Korean population. This tool includes three domain structures: items 1–3 measure alcohol consumption, items 4–6 assess AD, and items 7–10 evaluate alcohol-related harm.22,23 All items are equally weighted, the scores range from 0 to 4, and the total AUDIT score is determined by summing all subcategory scores; a higher AUDIT score is indicative of a higher risk in each category.

Genotyping of the BRAP and PRMT8 polymorphisms

To assess genomic DNA precisely, a DNA quantification analysis was performed using Quanti-iT PicoGreen fluorescence dye (Molecular Probes, Eugene, OR, USA). The quantification reactions were performed according to the manufacturer’s instructions (Manual No: MP0758) and the concentration of each type of genomic DNA was measured with a Fluorescence Reader (VICTOR2 fluorometer; Perkin Elmer, CA, USA). Candidate single-nucleotide polymorphisms (SNPs) of BRAP and PRMT8 were selected from among Japanese and Han Chinese genotype data using the 1,000 Genomes database (http://browser.1000genomes.org/index.html) based on the following conditions: 1) minor allele frequency (MAF) >5%; 2) linkage disequilibrium (LD) status based on an LD coefficient (r2) >0.98; 3) positions within the gene; and 4) amino acid changes. A total of 58 SNPs (5 from BRAP and 53 from PRMT8) were genotyped in the 459 alcoholic subjects and 455 nonalcoholic subjects using the Illumina Golden Gate genotyping system at a multiplex level.24 The genotyping quality score for retaining data was set to 0.25 and SNPs that did not satisfy the following criteria were excluded: 1) a minimum call rate of 95% and 2) no duplicate errors.

Statistical analysis

The LD was obtained using Haploview v4.2 software (http://www.broadinstitute.org/mpg/haploview) based on assessments of Lewontin’s D′ (|D′|) and the r2 between all pairs of biallelic loci.25 Haplotypes were determined using PHASE v2.0 software26 and comparisons of the genotype distributions between alcoholic and nonalcoholic subjects were carried out with a logistic regression model adjusted for age (continuous value) and sex (male =0, female =1) using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA). Associations between SNPs and AUDIT scores were also calculated using a linear regression model adjusted for age and sex. Statistical power of single associations was calculated using the Power for Genetic Association Analyses software,27 with false positive rate of 5%, disease prevalence of 4%,28 given MAFs and sample sizes, and assuming a relative risk of 1.5. Corrected P-values for multiple testing were calculated using the Bonferroni correction method.

Results

The present study included a total of 914 subjects who were categorized as either AD (n=459, mean age =47.37 years, range =21–80 years, 410 males and 49 females) or non-AD (n=455, mean age =44.21 years, range =20–79 years, 351 males and 104 females; Table 1); there were no significant differences between the AD and non-AD subjects in terms of age or sex. The degree of AD risk was estimated using AUDIT scores.

Table 1.

Clinical profiles of study subjects

Description AD Non-AD P-value
N 459 455
Age (year; mean-range) 47.37 (21–80) 44.21 (20–79) <0.001a
Gender (M/F) 410/49 351/104 <0.001b
AUDIT
 Overall 27.90±7.39 (0–40) 8.58±6.36 (0–29) <0.001a
 Alcohol consumption 10.23±2.10 (0–12) 5.73±3.46 (0–12) <0.001a
 Alcohol dependence 7.37±3.26 (0–12) 0.99±1.50 (0–8) <0.001a
 Alcohol-related harm 10.29±3.54 (0–16) 1.85±2.58 (0–14) <0.001a
Open in a new tab

Notes:

a

P-value was calculated using t-test analysis.

b

P-value was calculated using chi-square analysis.

Abbreviations: AD, alcohol dependence; AUDIT, Alcohol Use Disorders Identification Test; F, female; M, male.

Genotyping and haplotype analyses of BRAP and PRMT8 SNPs

A total of 58 SNPs (5 from BRAP and 53 from PRMT8) were genotyped in all subjects. The position, LD, and haplotype information of the investigated SNPs are shown in Figure S1. The BRAP and PRMT8 polymorphisms investigated in the present study were parsed into 1 LD block and 11 LD blocks, respectively. Not all haplotypes were selected for subsequent analyses because some haplotypes were tagged by SNPs on each gene.

Association analyses of BRAP and PRMT8 SNPs with AD

Logistic regression analyses were conducted to investigate the associations between BRAP and PRMT8 genetic variants and the risk of AD. In the case–control analysis, three genetic variants of BRAP (rs847895, rs3782886, and rs3803171) were associated with the risk of AD (minimum P=1.29×10−16, OR =0.19 at rs3782886) under the codominant model (Table 2). Of the PRMT8 SNPs, one genetic variant (rs12581829) was marginally associated with the risk of AD under the codominant model (P=0.02, OR =0.72) and two SNPs (rs4766138 and rs4766139) showed nominal associations with the risk of AD under the recessive model (P=0.002, OR =0.33 and P=0.0005, OR =0.30, respectively; Table S1). However, the statistical significance of the PRMT8 SNPs disappeared after corrections for multiple analyses were performed.

Table 2.

Follow-up analysis of BRAP polymorphisms with the risk of alcohol dependence in Korean subjects

Loci Allele Position (AA change) GWAS P-value MAF
Codominant
Dominant
Recessive
Statistical power (%)
AD Non- AD OR (95% CI) P-valuea Pcorrb OR (95% CI) P-valuea Pcorrb OR (95% CI) P-valuea
rs847895 A>G Intron 3 – 0.336 0.300 1.22 (1.00–1.50) 0.05 NS 1.23 (0.94–1.60) 0.13 – 1.47 (0.94–2.31) 0.09 98.6
rs3782886 A>G Exon 5 (R241R) 5.0×10−6 0.041 0.159 0.19 (0.13–0.28) 1.29×10−16 7.74×10−16 0.19 (0.13–0.28) 9.84×10−17 5.90×10−16 – – 25.2
rs3803171 G>T Intron 5 – 0.452 0.393 1.28 (1.06–1.56) 0.01 NS 1.31 (0.99–1.74) 0.06 – 1.51 (1.06–2.15) 0.02 98.5
rs3742001 A>G Intron 6 – 0.121 0.097 1.22 (0.89–1.67) 0.21 – 1.23 (0.89–1.71) 0.21 – 1.37 (0.25–7.58) 0.72 82.0
rs118186470 T>C Exon 11 (R472K) – 0.005 0.002 2.41 (0.43–13.46) 0.32 – 2.41 (0.43–13.46) 0.32 – – – 7.26
Frequency
ht1 0.502 0.444 1.29 (1.07–1.56) 0.009 NS 1.34 (1.00–1.81) 0.05 NS 1.48 (1.07–2.04) 0.02 97.32
Open in a new tab

Notes: Boldface indicates P-value ⩽0.05. P-values of GWAS represent the codominant model, which includes the additive model, adjusted for age and sex as covariates.

a

P-value of logistic analysis under additive model by adjusting for sex and age as covariates.

b

P-value after Bonferroni correction for multiple testing.

Abbreviations: AA, amino acid; AD, alcohol dependence; BRAP, BRCA1-associated protein; GWAS, genome-wide association study; MAF, minor allele frequency; ht, haplotype.

Associations of BRAP and PRMT8 SNPs with the degree of AD risk

To screen for the degree of risk of AD, additional association analyses between the AUDIT score and genetic variants of BRAP or PRMT8 that showed associations with the risk of AD were conducted. For BRAP, three SNPs (rs3803171, rs3782886, and rs847895) and one haplotype (ht1) were significantly associated with the overall AUDIT score (minimum P=9.94×10−31 and minimum Pcorr =5.96×10−30 at rs3782886) and three SNPs had significant association signals with alcohol use disorders (minimum P=3.30×10−46 and Pcorr =1.98×10−45 at rs3782886 for alcohol consumption, minimum P=1.95×10−17 and Pcorr =1.17×10−16 at rs3782886 for AD, and minimum P=3.89×10−22 and Pcorr =2.34×10−21 at rs3782886 for alcohol-related harm) based on the AUDIT scoring (Table 3). The strengths of the associations between the BRAP SNPs and alcohol use disorders were greater in non-AD subjects. Additionally, BRAP rs3782886 was strongly associated with the overall AUDIT score (P=1.40×10−24 and Pcorr =8.39×10−24) and the subcategories of the AUDIT (P=6.46×10−32 and Pcorr =3.87×10−31 for alcohol consumption, P=2.59×10−7 and Pcorr =1.56×10−6 for AD, and P=3.88×10−10, and Pcorr =2.32×10−9 for alcohol-related harm; Table 4).

Table 3.

Association analysis of BRAP polymorphisms with the AUDIT and subcategorical scores in all study subjects (n=914)

Category Loci C/C
C/R
R/R
P-valuea Pcorrb
N AUDIT score N AUDIT score N AUDIT score
AUDIT all rs847895 424 17.46±11.96 399 18.57±11.91 91 20.85±10.96 0.01 NS
rs3782886 736 20.36±11.12 173 9.94±11.08 5 1.20±1.64 9.94×10−31 5.96×10−30
rs3803171 299 16.81±11.88 455 18.46±12.14 158 20.37±10.69 0.002 0.01
ht1 250 16.54±11.96 463 18.43±12.20 201 20.09±10.71 0.0007 0.004
Alcohol consumption rs847895 424 7.81±3.70 399 8.02±3.68 91 8.68±3.07 0.06 –
rs3782886 736 8.73±3.15 173 5.06±3.91 5 0.40±0.55 3.30×10−46 1.98×10−45
rs3803171 299 7.61±3.70 455 8.00±3.77 158 8.64±3.02 0.005 0.02
ht1 250 7.29±3.88 463 7.98±3.73 201 8.89±2.84 3.36×10−07 2.02×10−6
Alcohol dependence rs847895 424 3.92±4.05 399 4.36±4.13 91 4.78±3.91 0.02 NS
rs3782886 736 4.74±4.06 173 2.01±3.35 5 0.00±0.00 1.95×10−17 1.17×10−16
rs3803171 299 3.75±4.04 455 4.33±4.10 158 4.57±3.97 0.03 NS
ht1 250 3.64±3.94 463 4.34±4.14 201 4.57±4.06 0.009 NS
Alcohol-related harm rs847895 424 5.73±5.29 399 6.18±5.16 91 7.38±5.22 0.007 NS
rs3782886 736 6.88±5.10 173 2.87±4.56 5 0.80±1.79 3.89×10−22 2.34×10−21
rs3803171 299 5.45±5.16 455 6.12±5.29 158 7.16±5.07 0.001 0.007
ht1 250 5.61±5.30 463 6.12±5.31 201 6.63±4.98 0.03 NS
Open in a new tab

Notes: C/C, C/R, and R/R mean major homozygote, heterozygote, and minor homozygote, respectively. AUDIT score is mean±SD. Boldface indicates P-value <0.05.

a

P-value of linear regression analysis under additive model by adjusting for sex and age as covariates.

b

P-value after Bonferroni correction for multiple testing.

Abbreviations: AUDIT, Alcohol Use Disorders Identification Test; BRAP, BRCA1-associated protein; ht, haplotype; NS, not significant.

Table 4.

Association analysis of BRAP polymorphisms with the AUDIT and subcategorical scores in non-alcohol dependence subjects (n=455)

Category Loci C/C
C/R
R/R
P-valuea Pcorrb
N AUDIT score N AUDIT score N AUDIT score
AUDIT all rs847895 221 7.91±5.92 195 9.00±6.83 39 10.21±6.01 0.007 0.04
rs3782886 315 10.26±6.23 135 4.91±4.88 5 1.20±1.64 1.40×10−24 8.39×10−24
rs3803171 163 7.87±5.94 226 8.62±6.65 66 10.17±6.15 0.004 0.02
ht1 138 7.44±6.35 230 8.52±6.47 87 10.53±5.65 0.0001 0.0006
Alcohol consumption rs847895 221 5.57±3.43 195 5.76±3.56 39 6.49±3.05 0.11 –
rs3782886 315 6.71±3.20 135 3.64±2.97 5 0.40±0.55 6.46×10−32 3.87×10−31
rs3803171 163 5.49±3.37 226 5.67±3.58 66 6.53±3.17 0.02 NS
ht1 138 4.97±3.58 230 5.61±3.42 87 7.24±2.89 1.02×10−07 6.13×10−7
Alcohol dependence rs847895 221 0.81±1.33 195 1.14±1.62 39 1.33±1.66 0.006 NS
rs3782886 315 1.22±1.59 135 0.50±1.11 5 0.00±0.00 2.59×10−07 1.56×10−6
rs3803171 163 0.75±1.22 226 1.10±1.62 66 1.24±1.61 0.004 0.02
ht1 138 0.89±1.45 230 1.06±1.60 87 0.99±1.26 0.58 –
Alcohol-related harm rs847895 221 1.54±2.26 195 2.10±2.87 39 2.38±2.62 0.008 0.04
rs3782886 315 2.33±2.76 135 0.77±1.71 5 0.80±1.79 3.88×10−10 2.32×10−9
rs3803171 163 1.63±2.38 226 1.86±2.56 66 2.39±3.04 0.03 NS
ht1 138 1.58±2.62 230 1.85±2.53 87 2.30±2.63 0.04 NS
Open in a new tab

Notes: C/C, C/R, and R/R mean major homozygote, heterozygote, and minor homozygote, respectively. AUDIT score is mean±SD. Boldface indicates P-value <0.05.

a

P-value of linear regression analysis under additive model by adjusting for sex and age as covariates.

b

P-value after Bonferroni correction for multiple testing.

Abbreviations: AUDIT, Alcohol Use Disorders Identification Test; BRAP, BRCA1-associated protein; ht, haplotype; NS, not significant.

The association analysis of the PRMT8 SNPs revealed that individuals with three SNPs (rs4766138, rs4766139, and rs12581829) showed a marginal association signal with the overall AUDIT score (P=0.01, 0.01, and 0.008, respectively; Table S2). However, the statistical significance of these associations disappeared after corrections for multiple analyses were performed.

Discussion

AD is a distressing chronic disease that results in significant human, social, and economic burdens.29 Drinking alcohol influences brain function by affecting brain tissues, brain cells, and the central nervous system (CNS). Accordingly, excessive alcohol consumption may result in severe deficits in cognition and memory function that are highly correlated with activity in nerve pathways.30 In a previous GWAS from our research group,18 BRAP and PRMT8 affected neurodevelopment in brain regions that were identified as having potential susceptibility loci for AD (P=4.65×10−6 at BRAP rs3782886 and P=1.77×10−5 at PRMT8 rs876594). Thus, BRAP and PRMT8 were proposed as novel candidate genes for controlling the amount of alcohol consumption.

BRAP is a regulatory protein that binds to several translocation signal proteins in the cytoplasm31 and, based on its functions, can modulate several intracellular signaling pathways. First, BRAP regulates the mitogen-activated protein kinase (MAPK) signaling pathway during CNS development through its function as a ubiquitin ligase.32 MAPK signaling is a known regulator of cell survival, proliferation, and differentiation as well as the production of proinflammatory cytokines. It has also been suggested that activation of the MAPK signaling pathway contributes to the neurotropic factor-mediated regulation of alcohol consumption.33 Second, BRAP acts as a primary mediator of inflammatory cascades by regulating the nuclear translocation of nuclear factor kappa B (NF-κB).34,35 A postmortem study in humans showed that NF-κB is downregulated in the brains of alcoholic patients.36 Similarly, other studies have shown that BRAP silencing via RNA interference inhibits NF-κB activation and that BRAP expression is ~twofold higher due to the genetic variant rs11066001, which is a tagging SNP of rs3782886 that has a high correlation value (r2=0.81).31,37,38 Taken together, these findings suggest that changes in BRAP expression induced by genetic variants might affect the NF-κB inflammatory cascade and may be a mechanism by which BRAP affects the risk level of AD. However, the direct and/or indirect functional impacts of BRAP on AD remain to be tested because the direct functional impacts of BRAP on several human disorders, including schizophrenia,31 myocardial infarction,39 carotid atherosclerosis,37 and metabolic syndrome,40 are not yet fully understood. However, the function of BRAP as a mediator of the translocation of signaling proteins might be a plausible explanation for the association between BRAP and human diseases with distinct pathophysiologies. Taken together, these data support the notion that BRAP has a genetic effect on alcohol-related disorders via the control of various signaling pathways.

PRMT8 is a member of the arginine methyltransferase gene family that influences several cellular processes, such as DNA repair, RNA transcription, and signal transduction, by methylating target regions.41 Of this protein family, only PRMT8 has an expression that is highly restricted to the CNS.42 Several studies have reported that arginine methylation is important for neurogenesis, which is essential for neurologic function.41,43 Although PRMT8 genetic variants showed nominal association signals with the risk of AD, genetic variants of PRMT8 might be implicated in the neuronal differentiation in the brain region.

Interestingly, the strength of the association between BRAP and alcohol use disorders was greater in nonalcoholic subjects than alcoholic subjects in the present study. BRAP is located a short distance from, and is affected by, the concomitant activity of ALDH2, which is highly related to AD. Thus, their association may be more prominent in nonalcoholic subjects because when ALDH2 induces lower rates of ALDH2 catalytic activity, even a small amount of alcohol consumption can cause a dramatic enhancement in acetaldehyde levels that triggers a highly aversion reaction. Therefore, these subjects may be classified as nonalcoholics even though there is an association between BRAP and alcohol use disorders. BRAP may also be a common gene associated with the characteristic patterns of alcohol use among nonalcoholic subjects. Taken together, these findings suggest that the effects of BRAP in nonalcoholics are very complicated and, as a result, interpretations of the present results should be made cautiously.

Although some evidence supports an association between BRAP and AD, it is also important to discuss the independent effects of this gene. There are strong LD values between BRAP rs3782886 and ALDH2 rs67144 and it will be difficult to identify strong genetic influences on AD pathophysiology that arise from only a single or several genes. On the other hand, AD pathophysiology is associated with several unexplained effects from single or several genes, that is, the roles that ADH and ALDH2 play in alcohol metabolism. Despite the fact that these effects are relatively small, many genes with limited effects may be involved in the pathophysiology of AD. Based on the polygenic hypothesis of AD pathophysiology, it is possible that multiple genetic loci in genes related to neurobiologic pathways could be associated with the risk of AD. Although BRAP has fewer independent effects in AD pathophysiology than ALDH2, BRAP may be involved in this process via the summation of many genes with small effects. The present findings suggest that BRAP may contribute to AD pathophysiology via contributions following the summation of its effects with the well-known effects of ALDH2.

Conclusion

Based on findings from a GWAS and a replication study of a Korean AD cohort, the present study was the first to propose that a BRAP SNP (rs3782886) was associated with AD. A future follow-up replication study using an independent sample may strengthen the present results and provide substantiation of the proposed polygenetic influences. Nevertheless, these novel findings provide important evidence that will contribute to the current understanding of the genetic etiology of AD as well as the development of assessments of AD risk that can be used in conjunction with conventional causal markers.

Supplementary materials

Figure S1

Haplotypes and LD structures of BRAP and PRMT8.

Notes: (A) Haplotypes of and (B) LDs among BRAP polymorphisms. (C) Haplotypes of and (D) LDs among PRMT8 polymorphisms.

Abbreviations: BRAP, BRCA1-associated protein; LD, linkage disequilibrium; PRMT8, protein arginine methyltransferase.

ndt-15-083s1.tif (418.8KB, tif)
ndt-15-083s1a.tif (706.5KB, tif)

Table S1.

Association analysis between PRMT8 SNPS and alcohol dependence subjects (n=914)

Loci Allele Position GWAS P-value MAF
Codominant
Dominant
Recessive
Statistical power (%)
AL Non-AL OR (95% CI) P-value* OR (95% CI) P-value* OR (95% CI) P-value*
rs34596546 T>C Intron – 0.038 0.032 1.17 (0.70–1.97) 0.55 1.17 (0.70–1.97) 0.55 – – 43.6
rs7303822 T>G Intron – 0.090 0.092 0.96 (0.69–1.33) 0.80 0.93 (0.66–1.32) 0.68 1.51 (0.35–6.52) 0.58 78.8
rs16930545 C>T Intron – 0.170 0.166 1.05 (0.81–1.35) 0.72 1.08 (0.81–1.43) 0.62 0.90 (0.38–2.12) 0.80 94.3
rs7972007 T>C Intron – 0.172 0.166 1.07 (0.83–1.38) 0.61 1.10 (0.83–1.46) 0.51 0.89 (0.38–2.11) 0.79 94.4
rs7972248 C>T Intron 0.02 0.388 0.407 0.93 (0.76–1.13) 0.45 0.90 (0.69–1.19) 0.48 0.91 (0.62–1.34) 0.64 99.1
rs7969082 G>A Intron 0.53 0.252 0.265 0.98 (0.79–1.21) 0.84 0.95 (0.73–1.24) 0.71 1.06 (0.63–1.79) 0.83 97.9
rs758612 A>C Intron 0.61 0.200 0.187 1.13 (0.88–1.43) 0.34 1.14 (0.86–1.50) 0.37 1.23 (0.58–2.61) 0.58 95.9
rs11062694 T>C Intron 0.03 0.191 0.193 0.96 (0.75–1.21) 0.70 0.93 (0.71–1.23) 0.61 1.06 (0.52–2.13) 0.88 96.0
rs11062697 C>A Intron 0.10 0.283 0.267 1.06 (0.86–1.30) 0.58 1.08 (0.82–1.40) 0.59 1.08 (0.67–1.74) 0.74 98.3
rs11062708 A>C Intron – 0.060 0.068 0.95 (0.64–1.40) 0.78 1.00 (0.67–1.50) 1 – – 61.6
rs10848873 A>C Intron 0.53 0.075 0.093 0.82 (0.58–1.17) 0.28 0.85 (0.60–1.22) 0.39 – – 68.3
rs11062709 G>A Intron – 0.176 0.178 0.98 (0.77–1.24) 0.84 0.97 (0.73–1.29) 0.86 0.95 (0.46–1.96) 0.89 95.0
rs12581198 G>A Intron – 0.459 0.447 1.02 (0.85–1.23) 0.83 1.06 (0.79–1.42) 0.69 0.99 (0.71–1.37) 0.94 99.2
rs10848876 T>C Intron – 0.480 0.493 0.94 (0.77–1.13) 0.50 1.12 (0.83–1.52) 0.46 0.74 (0.54–1.01) 0.06 99.2
rs3741938 T>C Intron 0.0006 0.461 0.462 1.01 (0.83–1.22) 0.95 1.14 (0.85–1.53) 0.38 0.86 (0.62–1.20) 0.38 99.3
rs3759363 A>G Intron 0.006 0.212 0.189 1.18 (0.93–1.51) 0.18 1.20 (0.91–1.59) 0.19 1.24 (0.57–2.70) 0.58 96.0
rs3759362 T>C Intron 0.0005 0.466 0.469 1.00 (0.82–1.21) 0.97 1.06 (0.79–1.43) 0.70 0.92 (0.67–1.28) 0.63 99.3
rs11062713 C>T Intron – 0.266 0.240 1.18 (0.94–1.47) 0.15 1.19 (0.91–1.56) 0.20 1.35 (0.76–2.40) 0.31 97.7
rs12423006 T>C Intron – 0.406 0.400 1.01 (0.83–1.24) 0.89 1.11 (0.84–1.47) 0.47 0.88 (0.60–1.27) 0.48 99.3
rs4766138 G>A Intron 0.02 0.198 0.226 0.84 (0.67–1.06) 0.14 0.96 (0.73–1.26) 0.74 0.33 (0.17–0.66) 0.002 95.2
rs7960599 A>G Intron – 0.108 0.102 1.09 (0.80–1.48) 0.59 1.03 (0.74–1.44) 0.84 3.64 (0.70–18.83) 0.12 83.8
rs2159404 T>C Intron – 0.473 0.460 1.03 (0.85–1.25) 0.76 1.04 (0.77–1.39) 0.81 1.04 (0.76–1.44) 0.79 99.2
rs876594 C>T Intron 0.00002 0.362 0.373 0.96 (0.78–1.16) 0.64 1.03 (0.78–1.35) 0.85 0.79 (0.53–1.17) 0.23 99.1
rs4766139 C>T Intron 0.03 0.205 0.234 0.84 (0.67–1.05) 0.13 0.98 (0.74–1.28) 0.86 0.30 (0.15–0.59) 0.0005 95.7
rs10848881 A>C Intron – 0.059 0.065 0.96 (0.65–1.41) 0.82 0.97 (0.64–1.45) 0.86 0.64 (0.06–7.10) 0.71 61.5
rs10774155 C>T Intron – 0.179 0.177 1.04 (0.81–1.33) 0.77 1.15 (0.87–1.52) 0.34 0.50 (0.22–1.13) 0.10 95.2
rs10774156 C>A Intron 0.005 0.451 0.434 1.05 (0.87–1.28) 0.60 1.13 (0.84–1.50) 0.42 1.00 (0.71–1.40) 0.99 99.2
rs11614792 T>C Intron – 0.492 0.501 0.96 (0.80–1.17) 0.71 1.07 (0.79–1.46) 0.66 0.85 (0.62–1.16) 0.29 99.2
rs9669266 A>G Intron – 0.369 0.390 0.91 (0.75–1.10) 0.33 0.98 (0.75–1.29) 0.91 0.71 (0.48–1.04) 0.08 99.0
rs12581829 A>C Intron – 0.105 0.137 0.72 (0.54–0.96) 0.02 0.71 (0.51–0.97) 0.03 0.52 (0.20–1.36) 0.18 79.1
rs10774158 G>A Intron 0.09 0.179 0.179 1.02 (0.80–1.31) 0.85 1.14 (0.86–1.52) 0.36 0.46 (0.20–1.04) 0.06 95.3
rs4766141 C>G Intron – 0.210 0.187 1.16 (0.91–1.47) 0.24 1.16 (0.88–1.53) 0.30 1.39 (0.68–2.87) 0.37 95.9
rs3782749 T>G Intron – 0.054 0.064 0.90 (0.60–1.34) 0.60 0.90 (0.59–1.37) 0.63 0.64 (0.06–7.08) 0.71 56.6
rs11062723 G>A Intron – 0.409 0.393 1.07 (0.88–1.30) 0.52 1.12 (0.85–1.48) 0.41 1.03 (0.71–1.48) 0.90 99.2
rs3825339 A>G Intron – 0.224 0.210 1.10 (0.88–1.39) 0.40 1.13 (0.86–1.48) 0.40 1.12 (0.59–2.12) 0.74 96.9
rs3741936 G>A Intron 0.14 0.272 0.285 0.93 (0.75–1.15) 0.49 0.92 (0.70–1.20) 0.52 0.90 (0.53–1.53) 0.69 98.3
rs917602 G>A Intron 0.28 0.264 0.253 1.05 (0.85–1.31) 0.63 1.11 (0.85–1.45) 0.44 0.92 (0.55–1.55) 0.75 98.1
rs7966000 A>G Intron – 0.136 0.156 0.82 (0.63–1.08) 0.16 0.81 (0.60–1.09) 0.16 0.76 (0.28–2.11) 0.60 88.8
rs7957814 G.A Intron 0.15 0.111 0.113 0.98 (0.73–1.32) 0.89 0.97 (0.70–1.34) 0.85 1.14 (0.30–4.36) 0.84 85.5
rs6489480 A.G Intron – 0.111 0.114 0.97 (0.72–1.31) 0.84 0.96 (0.69–1.32) 0.79 1.14 (0.30–4.36) 0.84 85.2
rs3782745 A.C Intron – 0.053 0.045 1.17 (0.76–1.79) 0.48 1.10 (0.70–1.72) 0.68 – – 55.7
rs7307502 A.G Intron – 0.176 0.176 0.97 (0.76–1.24) 0.82 0.94 (0.70–1.24) 0.65 1.23 (0.57–2.65) 0.61 95.1
rs3782744 G.A Intron 0.44 0.479 0.464 1.09 (0.91–1.32) 0.34 0.98 (0.74–1.32) 0.91 1.33 (0.97–1.82) 0.08 99.2
rs7976970 A.G Intron 0.14 0.115 0.115 1.00 (0.74–1.35) 0.99 0.99 (0.72–1.37) 0.97 1.14 (0.30–4.36) 0.84 86.7
rs16930578 G.A Intron 0.11 0.083 0.077 1.07 (0.75–1.52) 0.72 1.10 (0.76–1.58) 0.62 0.42 (0.04–4.69) 0.48 74.7
rs758637 G.A Intron 0.93 0.381 0.382 0.98 (0.81–1.18) 0.80 0.89 (0.68–1.17) 0.41 1.13 (0.78–1.63) 0.53 99.2
rs7137875 A.G Intron 0.34 0.137 0.149 0.89 (0.68–1.16) 0.38 0.88 (0.66–1.19) 0.41 0.76 (0.28–2.11) 0.60 89.7
rs11062731 G.C Intron – 0.129 0.138 0.90 (0.68–1.20) 0.47 0.90 (0.66–1.22) 0.50 0.81 (0.27–2.50) 0.72 88.7
rs11062733 C.T Intron 0.22 0.099 0.102 0.94 (0.68–1.29) 0.69 0.94 (0.68–1.32) 0.73 0.69 (0.11–4.31) 0.69 81.7
rs4765741 G.A Intron 0.47 0.479 0.466 1.08 (0.90–1.30) 0.42 0.99 (0.74–1.32) 0.92 1.27 (0.93–1.74) 0.14 99.2
rs11830814 G.C Intergenic – 0.082 0.078 1.06 (0.74–1.50) 0.76 1.08 (0.75–1.56) 0.67 0.42 (0.04–4.69) 0.48 74.8
rs2159347 C.T Intergenic – 0.117 0.091 1.31 (0.96–1.78) 0.09 1.35 (0.97–1.88) 0.08 1.21 (0.31–4.65) 0.79 82.5
rs1029766 G.A Intergenic 0.77 0.402 0.407 0.97 (0.80–1.17) 0.72 0.86 (0.65–1.13) 0.28 1.14 (0.80–1.62) 0.47 99.3
Frequency
BL1_ht1 0.441 0.429 1.03 (0.85–1.25) 0.74 1.10 (0.82–1.46) 0.53 0.97 (0.69–1.37) 0.88 99.1
BL1_ht4 0.081 0.074 1.19 (0.82–1.72) 0.35 1.19 (0.82–1.72) 0.35 – – 71.3
BL2_ht1 0.461 0.455 1.03 (0.85–1.25) 0.76 1.13 (0.85–1.52) 0.40 0.93 (0.67–1.30) 0.69 99.2
BL3_ht3 0.062 0.055 1.12 (0.75–1.66) 0.59 1.19 (0.78–1.82) 0.41 0.27 (0.03–2.68) 0.27 59.8
BL4_ht3 0.158 0.138 1.19 (0.91–1.56) 0.20 1.16 (0.86–1.56) 0.32 2.14 (0.72–6.34) 0.17 89.3
BL4_ht5 0.065 0.060 1.04 (0.71–1.54) 0.84 1.09 (0.72–1.63) 0.69 0.29 (0.03–3.29) 0.32 63.4
BL4_ht6 0.056 0.064 0.92 (0.62–1.38) 0.70 0.96 (0.63–1.44) 0.83 – – 56.3
BL5_ht2 0.370 0.389 0.93 (0.76–1.13) 0.44 1.01 (0.77–1.33) 0.94 0.73 (0.49–1.07) 0.10 98.8
BL5_ht3 0.121 0.112 1.09 (0.81–1.47) 0.57 1.09 (0.80–1.50) 0.59 1.21 (0.33–4.40) 0.77 85.1
BL6_ht2 0.265 0.253 1.08 (0.87–1.35) 0.48 1.09 (0.84–1.43) 0.51 1.13 (0.62–2.05) 0.69 97.8
BL6_ht3 0.125 0.116 1.09 (0.82–1.46) 0.55 1.11 (0.81–1.53) 0.50 0.94 (0.27–3.23) 0.92 86.1
BL7_ht2 0.205 0.241 0.81 (0.65–1.02) 0.07 0.94 (0.72–1.24) 0.68 0.28 (0.14–0.55) 0.0002 93.6
BL7_ht4 0.123 0.115 1.08 (0.81–1.45) 0.60 1.10 (0.80–1.51) 0.55 0.94 (0.27–3.23) 0.92 85.9
BL8_ht1 0.467 0.466 1.02 (0.85–1.22) 0.85 0.91 (0.68–1.21) 0.51 1.18 (0.86–1.61) 0.31 99.3
BL10_ht2 0.341 0.356 0.92 (0.76–1.12) 0.41 0.83 (0.63–1.08) 0.16 1.09 (0.73–1.64) 0.68 98.8
BL11_ht2 0.288 0.319 0.85 (0.69–1.04) 0.12 0.82 (0.63–1.06) 0.13 0.81 (0.51–1.30) 0.38 97.5
Open in a new tab

Notes: Boldface indicates P-value <0.05. P-values of GWAS represent the codominant model, which includes the additive model, adjusted for age and sex as covariates.

*

P-value of logistic analysis under additive model by adjusting for sex and age as covariates.

Abbreviations: AA, amino acid; AL, alcoholic subjects; GWAS, genome-wide association study; ht, haplotype; MAF, minor allele frequency; PRMT8, protein arginine methyltransferase.

Table S2.

Association analysis of PRMT8 SNPs with the AUDIT score in all study subjects (n=914)

Category Loci C/C
C/R
R/R
P-value*
N AUDIT score N AUDIT score N AUDIT score
AUDIT all rs4766138 572 18.77±11.79 296 18.20±11.81 46 12.65±12.10 0.01
rs4766139 562 18.75±11.79 303 18.36±11.82 49 12.33±11.80 0.01
rs12581829 711 18.81±11.76 183 16.34±12.01 19 16.21±13.06 0.008
Alcohol consumption rs4766138 572 8.12±3.58 296 7.98±3.61 46 6.48±4.25 0.04
rs4766139 562 8.12±3.58 303 8.01±3.61 49 6.43±4.13 0.03
rs12581829 711 8.13±3.56 183 7.45±3.88 19 7.74±3.86 0.03
Alcohol dependence rs4766138 572 4.31±4.10 296 4.21±4.02 46 2.74±3.87 0.08
rs4766139 562 4.28±4.09 303 4.30±4.05 49 2.59±3.80 0.09
rs12581829 711 4.30±4.08 183 3.83±4.03 19 3.53±4.36 0.09
Alcohol-related harm rs4766138 572 6.34±5.22 296 6.02±5.21 46 3.43±4.96 0.005
rs4766139 562 6.35±5.23 303 6.06±5.20 49 3.31±4.86 0.003
rs12581829 711 6.38±5.23 183 5.07±5.11 19 4.95±5.71 0.001
Open in a new tab

Notes: C/C, C/R, and R/R mean major homozygote, heterozygote, and minor homozygote, respectively. AUDIT score is mean±SD.

*

P-value of linear regression analysis under additive model by adjusting for sex and age as covariates. Boldface indicates P-value <0.05.

Abbreviations: AUDIT, Alcohol Use Disorders Identification Test; PRMT8, protein arginine methyltransferase.

Acknowledgments

This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (grant number A084589) and a grant from Hallym University Research Fund 2015, Republic of Korea (HRF-2015–28). This paper was presented at the 16th World Congress of Psychiatry, Madrid, Spain, as an abstract presentation with interim findings on September 15, 2014.

Footnotes

Disclosure

Byung Lae Park is an employee and Hyung Doo Shin is the CEO of SNP Genetics, Inc., which is located at #TE1007, Teilhard Hall, Sogang University, Shinsu-dong, Mapo-gu, Seoul, 121-742, Republic of Korea. This company provided the iScan scanner instrument and BeadStudio 3.0 software used in the research. They were also involved in the study design, data collection and analysis, decision to publish, and preparation of the manuscript. However, these competing interests did not alter the authors’ adherence to all policies of Neuropsychiatric Disease and Treatment. The others authors report no conflicts of interest in this work.

References

  • 1.Prom-Wormley EC, Ebejer J, Dick DM, Bowers MS. The genetic epidemiology of substance use disorder: a review. Drug Alcohol Depend. 2017;180:241–259. doi: 10.1016/j.drugalcdep.2017.06.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Zollanvari A, Alterovitz G. SNP by SNP by environment interaction network of alcoholism. BMC Syst Biol. 2017;11(Suppl 3):19. doi: 10.1186/s12918-017-0403-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gordis E. Genes and the environment in complex diseases: a focus on alcoholism. Mol Psychiatry. 1997;2(4):282–286. doi: 10.1038/sj.mp.4000296. [DOI] [PubMed] [Google Scholar]
  • 4.Kendler KS, Heath AC, Neale MC, Kessler RC, Eaves LJ. A population-based twin study of alcoholism in women. JAMA. 1992;268(14):1877–1882. [PubMed] [Google Scholar]
  • 5.Prescott CA, Kendler KS. Genetic and environmental contributions to alcohol abuse and dependence in a population-based sample of male twins. Am J Psychiatry. 1999;156(1):34–40. doi: 10.1176/ajp.156.1.34. [DOI] [PubMed] [Google Scholar]
  • 6.Bohman M, Sigvardsson S, Cloninger CR. Maternal inheritance of alcohol abuse. Cross-fostering analysis of adopted women. Arch Gen Psychiatry. 1981;38(9):965–969. doi: 10.1001/archpsyc.1981.01780340017001. [DOI] [PubMed] [Google Scholar]
  • 7.Sigvardsson S, Bohman M, Cloninger CR. Replication of the stockholm adoption study of alcoholism. Confirmatory cross-fostering analysis. Arch Gen Psychiatry. 1996;53(8):681–687. doi: 10.1001/archpsyc.1996.01830080033007. [DOI] [PubMed] [Google Scholar]
  • 8.Kendler KS, Neale MC, Heath AC, Kessler RC, Eaves LJ. A twin-family study of alcoholism in women. Am J Psychiatry. 1994;151(5):707–715. doi: 10.1176/ajp.151.5.707. [DOI] [PubMed] [Google Scholar]
  • 9.Choi IG, Son HG, Yang BH, et al. Scanning of genetic effects of alcohol metabolism gene (ADH1B and ADH1C) polymorphisms on the risk of alcoholism. Hum Mutat. 2005;26(3):224–234. doi: 10.1002/humu.20209. [DOI] [PubMed] [Google Scholar]
  • 10.Edenberg HJ, Xuei X, Chen HJ, et al. Association of alcohol dehydrogenase genes with alcohol dependence: a comprehensive analysis. Hum Mol Genet. 2006;15(9):1539–1549. doi: 10.1093/hmg/ddl073. [DOI] [PubMed] [Google Scholar]
  • 11.Kim DJ, Choi IG, Park BL, et al. Major genetic components underlying alcoholism in Korean population. Hum Mol Genet. 2008;17(6):854–858. doi: 10.1093/hmg/ddm357. [DOI] [PubMed] [Google Scholar]
  • 12.Samochowiec J, Samochowiec A, Puls I, Bienkowski P, Schott BH. Genetics of alcohol dependence: a review of clinical studies. Neuropsychobiology. 2014;70(2):77–94. doi: 10.1159/000364826. [DOI] [PubMed] [Google Scholar]
  • 13.Thompson MD, Kenna GA. Variation in the serotonin transporter gene and alcoholism: risk and response to pharmacotherapy. Alcohol Alcohol. 2016;51(2):164–171. doi: 10.1093/alcalc/agv090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Bierut LJ, Agrawal A, Bucholz KK, et al. Gene, Environment Association Studies Consortium A genome-wide association study of alcohol dependence. Proc Natl Acad Sci U S A. 2010;107(11):5082–5087. doi: 10.1073/pnas.0911109107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Lind PA, Macgregor S, Vink JM, et al. A genomewide association study of nicotine and alcohol dependence in Australian and Dutch populations. Twin Res Hum Genet. 2010;13(1):10–29. doi: 10.1375/twin.13.1.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Zuo L, Zhang XY, Wang F, et al. Genome-wide significant association signals in IPO11-HTR1A region specific for alcohol and nicotine codependence. Alcohol Clin Exp Res. 2013;37(5):730–739. doi: 10.1111/acer.12032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Baik I, Cho NH, Kim SH, Han BG, Shin C. Genome-wide association studies identify genetic loci related to alcohol consumption in Korean men. Am J Clin Nutr. 2011;93(4):809–816. doi: 10.3945/ajcn.110.001776. [DOI] [PubMed] [Google Scholar]
  • 18.Park BL, Kim JW, Cheong HS, et al. Extended genetic effects of ADH cluster genes on the risk of alcohol dependence: from GWAS to replication. Hum Genet. 2013;132(6):657–668. doi: 10.1007/s00439-013-1281-8. [DOI] [PubMed] [Google Scholar]
  • 19.Joe KH, Kim DJ, Park BL, et al. Genetic association of DRD2 polymorphisms with anxiety scores among alcohol-dependent patients. Biochem Biophys Res Commun. 2008;371(4):591–595. doi: 10.1016/j.bbrc.2008.02.076. [DOI] [PubMed] [Google Scholar]
  • 20.American Psychiatric Association . American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994. [Google Scholar]
  • 21.Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption – II. Addiction. 1993;88(6):791–804. doi: 10.1111/j.1360-0443.1993.tb02093.x. [DOI] [PubMed] [Google Scholar]
  • 22.Sung J, Lee K, Song YM. Heritabilities of Alcohol Use Disorders Identification Test (AUDIT) scores and alcohol biomarkers in Koreans: the KoGES (Korean Genome Epi Study) and Healthy Twin Study. Drug Alcohol Depend. 2011;113(2–3):104–109. doi: 10.1016/j.drugalcdep.2010.07.012. [DOI] [PubMed] [Google Scholar]
  • 23.Tsai MC, Tsai YF, Chen CY, Liu CY. Alcohol Use Disorders Identification Test (AUDIT): establishment of cut-off scores in a hospitalized Chinese population. Alcohol Clin Exp Res. 2005;29(1):53–57. doi: 10.1097/01.alc.0000151986.96710.e0. [DOI] [PubMed] [Google Scholar]
  • 24.Oliphant A, Barker DL, Stuelpnagel JR, Chee MS. BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques. 2002;(Suppl):S56–S61. [PubMed] [Google Scholar]
  • 25.Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–265. doi: 10.1093/bioinformatics/bth457. [DOI] [PubMed] [Google Scholar]
  • 26.Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68(4):978–989. doi: 10.1086/319501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Menashe I, Rosenberg PS, Chen BE. PGA: power calculator for case-control genetic association analyses. BMC Genet. 2008;9:36. doi: 10.1186/1471-2156-9-36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ezzati M, Lopez AD, Rodgers A, vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating Group Selected major risk factors and global and regional burden of disease. Lancet. 2002;360(9343):1347–1360. doi: 10.1016/S0140-6736(02)11403-6. [DOI] [PubMed] [Google Scholar]
  • 29.Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature. 2011;475(7354):27–30. doi: 10.1038/475027a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kim JW, Lee DY, Lee BC, et al. Alcohol and cognition in the elderly: a review. Psychiatry Investig. 2012;9(1):8–16. doi: 10.4306/pi.2012.9.1.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Zhang F, Liu C, Xu Y, et al. A two-stage association study suggests BRAP as a susceptibility gene for schizophrenia. PLoS One. 2014;9(1):e86037. doi: 10.1371/journal.pone.0086037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Lanctot AA, Peng CY, Pawlisz AS, Joksimovic M, Feng Y. Spatially dependent dynamic MAPK modulation by the Nde1-Lis1-Brap complex patterns mammalian CNS. Dev Cell. 2013;25(3):241–255. doi: 10.1016/j.devcel.2013.04.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Jeanblanc J, Logrip ML, Janak PH, Ron D. BDNF-mediated regulation of ethanol consumption requires the activation of the MAP kinase pathway and protein synthesis. Eur J Neurosci. 2013;37(4):607–612. doi: 10.1111/ejn.12067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Takashima O, Tsuruta F, Kigoshi Y, et al. Brap2 regulates temporal control of NF-κB localization mediated by inflammatory response. PLoS One. 2013;8(3):e58911. doi: 10.1371/journal.pone.0058911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Plestant C, Anton ES. Scaling the MAPK signaling threshold during CNS patterning. Dev Cell. 2013;25(3):221–222. doi: 10.1016/j.devcel.2013.04.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Okvist A, Johansson S, Kuzmin A, et al. Neuroadaptations in human chronic alcoholics: dysregulation of the NF-kappaB system. PLoS One. 2007;2(9):e930. doi: 10.1371/journal.pone.0000930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Liao YC, Wang YS, Guo YC, et al. BRAP Activates inflammatory cascades and increases the risk for carotid atherosclerosis. Mol Med. 2011;17(9–10):1065–1074. doi: 10.2119/molmed.2011.00043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Tsai PC, Liao YC, Lin TH, Hsi E, Yang YH, Juo SH. Additive effect of ANRIL and BRAP polymorphisms on ankle-brachial index in a Taiwanese population. Circ J. 2012;76(2):446–452. doi: 10.1253/circj.cj-11-0925. [DOI] [PubMed] [Google Scholar]
  • 39.Ozaki K, Sato H, Inoue K, et al. SNPs in BRAP associated with risk of myocardial infarction in Asian populations. Nat Genet. 2009;41(3):329–333. doi: 10.1038/ng.326. [DOI] [PubMed] [Google Scholar]
  • 40.Avery CL, He Q, North KE, et al. A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains. PLoS Genet. 2011;7(10):e1002322. doi: 10.1371/journal.pgen.1002322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Dillon MB, Rust HL, Thompson PR, Mowen KA. Automethylation of protein arginine methyltransferase 8 (PRMT8) regulates activity by impeding S-adenosylmethionine sensitivity. J Biol Chem. 2013;288(39):27872–27880. doi: 10.1074/jbc.M113.491092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Lee J, Sayegh J, Daniel J, Clarke S, Bedford MT. PRMT8, a new membrane-bound tissue-specific member of the protein arginine methyltransferase family. J Biol Chem. 2005;280(38):32890–32896. doi: 10.1074/jbc.M506944200. [DOI] [PubMed] [Google Scholar]
  • 43.Kim S, Parks CG, Xu Z, et al. Association between genetic variants in DNA and histone methylation and telomere length. PLoS One. 2012;7(7):e40504. doi: 10.1371/journal.pone.0040504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Kamatani Y, Matsuda K, Okada Y, et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet. 2010;42:210–215. doi: 10.1038/ng.531. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Figure S1

Haplotypes and LD structures of BRAP and PRMT8.

Notes: (A) Haplotypes of and (B) LDs among BRAP polymorphisms. (C) Haplotypes of and (D) LDs among PRMT8 polymorphisms.

Abbreviations: BRAP, BRCA1-associated protein; LD, linkage disequilibrium; PRMT8, protein arginine methyltransferase.

ndt-15-083s1.tif (418.8KB, tif)
ndt-15-083s1a.tif (706.5KB, tif)

Table S1.

Association analysis between PRMT8 SNPS and alcohol dependence subjects (n=914)

Loci Allele Position GWAS P-value MAF
Codominant
Dominant
Recessive
Statistical power (%)
AL Non-AL OR (95% CI) P-value* OR (95% CI) P-value* OR (95% CI) P-value*
rs34596546 T>C Intron – 0.038 0.032 1.17 (0.70–1.97) 0.55 1.17 (0.70–1.97) 0.55 – – 43.6
rs7303822 T>G Intron – 0.090 0.092 0.96 (0.69–1.33) 0.80 0.93 (0.66–1.32) 0.68 1.51 (0.35–6.52) 0.58 78.8
rs16930545 C>T Intron – 0.170 0.166 1.05 (0.81–1.35) 0.72 1.08 (0.81–1.43) 0.62 0.90 (0.38–2.12) 0.80 94.3
rs7972007 T>C Intron – 0.172 0.166 1.07 (0.83–1.38) 0.61 1.10 (0.83–1.46) 0.51 0.89 (0.38–2.11) 0.79 94.4
rs7972248 C>T Intron 0.02 0.388 0.407 0.93 (0.76–1.13) 0.45 0.90 (0.69–1.19) 0.48 0.91 (0.62–1.34) 0.64 99.1
rs7969082 G>A Intron 0.53 0.252 0.265 0.98 (0.79–1.21) 0.84 0.95 (0.73–1.24) 0.71 1.06 (0.63–1.79) 0.83 97.9
rs758612 A>C Intron 0.61 0.200 0.187 1.13 (0.88–1.43) 0.34 1.14 (0.86–1.50) 0.37 1.23 (0.58–2.61) 0.58 95.9
rs11062694 T>C Intron 0.03 0.191 0.193 0.96 (0.75–1.21) 0.70 0.93 (0.71–1.23) 0.61 1.06 (0.52–2.13) 0.88 96.0
rs11062697 C>A Intron 0.10 0.283 0.267 1.06 (0.86–1.30) 0.58 1.08 (0.82–1.40) 0.59 1.08 (0.67–1.74) 0.74 98.3
rs11062708 A>C Intron – 0.060 0.068 0.95 (0.64–1.40) 0.78 1.00 (0.67–1.50) 1 – – 61.6
rs10848873 A>C Intron 0.53 0.075 0.093 0.82 (0.58–1.17) 0.28 0.85 (0.60–1.22) 0.39 – – 68.3
rs11062709 G>A Intron – 0.176 0.178 0.98 (0.77–1.24) 0.84 0.97 (0.73–1.29) 0.86 0.95 (0.46–1.96) 0.89 95.0
rs12581198 G>A Intron – 0.459 0.447 1.02 (0.85–1.23) 0.83 1.06 (0.79–1.42) 0.69 0.99 (0.71–1.37) 0.94 99.2
rs10848876 T>C Intron – 0.480 0.493 0.94 (0.77–1.13) 0.50 1.12 (0.83–1.52) 0.46 0.74 (0.54–1.01) 0.06 99.2
rs3741938 T>C Intron 0.0006 0.461 0.462 1.01 (0.83–1.22) 0.95 1.14 (0.85–1.53) 0.38 0.86 (0.62–1.20) 0.38 99.3
rs3759363 A>G Intron 0.006 0.212 0.189 1.18 (0.93–1.51) 0.18 1.20 (0.91–1.59) 0.19 1.24 (0.57–2.70) 0.58 96.0
rs3759362 T>C Intron 0.0005 0.466 0.469 1.00 (0.82–1.21) 0.97 1.06 (0.79–1.43) 0.70 0.92 (0.67–1.28) 0.63 99.3
rs11062713 C>T Intron – 0.266 0.240 1.18 (0.94–1.47) 0.15 1.19 (0.91–1.56) 0.20 1.35 (0.76–2.40) 0.31 97.7
rs12423006 T>C Intron – 0.406 0.400 1.01 (0.83–1.24) 0.89 1.11 (0.84–1.47) 0.47 0.88 (0.60–1.27) 0.48 99.3
rs4766138 G>A Intron 0.02 0.198 0.226 0.84 (0.67–1.06) 0.14 0.96 (0.73–1.26) 0.74 0.33 (0.17–0.66) 0.002 95.2
rs7960599 A>G Intron – 0.108 0.102 1.09 (0.80–1.48) 0.59 1.03 (0.74–1.44) 0.84 3.64 (0.70–18.83) 0.12 83.8
rs2159404 T>C Intron – 0.473 0.460 1.03 (0.85–1.25) 0.76 1.04 (0.77–1.39) 0.81 1.04 (0.76–1.44) 0.79 99.2
rs876594 C>T Intron 0.00002 0.362 0.373 0.96 (0.78–1.16) 0.64 1.03 (0.78–1.35) 0.85 0.79 (0.53–1.17) 0.23 99.1
rs4766139 C>T Intron 0.03 0.205 0.234 0.84 (0.67–1.05) 0.13 0.98 (0.74–1.28) 0.86 0.30 (0.15–0.59) 0.0005 95.7
rs10848881 A>C Intron – 0.059 0.065 0.96 (0.65–1.41) 0.82 0.97 (0.64–1.45) 0.86 0.64 (0.06–7.10) 0.71 61.5
rs10774155 C>T Intron – 0.179 0.177 1.04 (0.81–1.33) 0.77 1.15 (0.87–1.52) 0.34 0.50 (0.22–1.13) 0.10 95.2
rs10774156 C>A Intron 0.005 0.451 0.434 1.05 (0.87–1.28) 0.60 1.13 (0.84–1.50) 0.42 1.00 (0.71–1.40) 0.99 99.2
rs11614792 T>C Intron – 0.492 0.501 0.96 (0.80–1.17) 0.71 1.07 (0.79–1.46) 0.66 0.85 (0.62–1.16) 0.29 99.2
rs9669266 A>G Intron – 0.369 0.390 0.91 (0.75–1.10) 0.33 0.98 (0.75–1.29) 0.91 0.71 (0.48–1.04) 0.08 99.0
rs12581829 A>C Intron – 0.105 0.137 0.72 (0.54–0.96) 0.02 0.71 (0.51–0.97) 0.03 0.52 (0.20–1.36) 0.18 79.1
rs10774158 G>A Intron 0.09 0.179 0.179 1.02 (0.80–1.31) 0.85 1.14 (0.86–1.52) 0.36 0.46 (0.20–1.04) 0.06 95.3
rs4766141 C>G Intron – 0.210 0.187 1.16 (0.91–1.47) 0.24 1.16 (0.88–1.53) 0.30 1.39 (0.68–2.87) 0.37 95.9
rs3782749 T>G Intron – 0.054 0.064 0.90 (0.60–1.34) 0.60 0.90 (0.59–1.37) 0.63 0.64 (0.06–7.08) 0.71 56.6
rs11062723 G>A Intron – 0.409 0.393 1.07 (0.88–1.30) 0.52 1.12 (0.85–1.48) 0.41 1.03 (0.71–1.48) 0.90 99.2
rs3825339 A>G Intron – 0.224 0.210 1.10 (0.88–1.39) 0.40 1.13 (0.86–1.48) 0.40 1.12 (0.59–2.12) 0.74 96.9
rs3741936 G>A Intron 0.14 0.272 0.285 0.93 (0.75–1.15) 0.49 0.92 (0.70–1.20) 0.52 0.90 (0.53–1.53) 0.69 98.3
rs917602 G>A Intron 0.28 0.264 0.253 1.05 (0.85–1.31) 0.63 1.11 (0.85–1.45) 0.44 0.92 (0.55–1.55) 0.75 98.1
rs7966000 A>G Intron – 0.136 0.156 0.82 (0.63–1.08) 0.16 0.81 (0.60–1.09) 0.16 0.76 (0.28–2.11) 0.60 88.8
rs7957814 G.A Intron 0.15 0.111 0.113 0.98 (0.73–1.32) 0.89 0.97 (0.70–1.34) 0.85 1.14 (0.30–4.36) 0.84 85.5
rs6489480 A.G Intron – 0.111 0.114 0.97 (0.72–1.31) 0.84 0.96 (0.69–1.32) 0.79 1.14 (0.30–4.36) 0.84 85.2
rs3782745 A.C Intron – 0.053 0.045 1.17 (0.76–1.79) 0.48 1.10 (0.70–1.72) 0.68 – – 55.7
rs7307502 A.G Intron – 0.176 0.176 0.97 (0.76–1.24) 0.82 0.94 (0.70–1.24) 0.65 1.23 (0.57–2.65) 0.61 95.1
rs3782744 G.A Intron 0.44 0.479 0.464 1.09 (0.91–1.32) 0.34 0.98 (0.74–1.32) 0.91 1.33 (0.97–1.82) 0.08 99.2
rs7976970 A.G Intron 0.14 0.115 0.115 1.00 (0.74–1.35) 0.99 0.99 (0.72–1.37) 0.97 1.14 (0.30–4.36) 0.84 86.7
rs16930578 G.A Intron 0.11 0.083 0.077 1.07 (0.75–1.52) 0.72 1.10 (0.76–1.58) 0.62 0.42 (0.04–4.69) 0.48 74.7
rs758637 G.A Intron 0.93 0.381 0.382 0.98 (0.81–1.18) 0.80 0.89 (0.68–1.17) 0.41 1.13 (0.78–1.63) 0.53 99.2
rs7137875 A.G Intron 0.34 0.137 0.149 0.89 (0.68–1.16) 0.38 0.88 (0.66–1.19) 0.41 0.76 (0.28–2.11) 0.60 89.7
rs11062731 G.C Intron – 0.129 0.138 0.90 (0.68–1.20) 0.47 0.90 (0.66–1.22) 0.50 0.81 (0.27–2.50) 0.72 88.7
rs11062733 C.T Intron 0.22 0.099 0.102 0.94 (0.68–1.29) 0.69 0.94 (0.68–1.32) 0.73 0.69 (0.11–4.31) 0.69 81.7
rs4765741 G.A Intron 0.47 0.479 0.466 1.08 (0.90–1.30) 0.42 0.99 (0.74–1.32) 0.92 1.27 (0.93–1.74) 0.14 99.2
rs11830814 G.C Intergenic – 0.082 0.078 1.06 (0.74–1.50) 0.76 1.08 (0.75–1.56) 0.67 0.42 (0.04–4.69) 0.48 74.8
rs2159347 C.T Intergenic – 0.117 0.091 1.31 (0.96–1.78) 0.09 1.35 (0.97–1.88) 0.08 1.21 (0.31–4.65) 0.79 82.5
rs1029766 G.A Intergenic 0.77 0.402 0.407 0.97 (0.80–1.17) 0.72 0.86 (0.65–1.13) 0.28 1.14 (0.80–1.62) 0.47 99.3
Frequency
BL1_ht1 0.441 0.429 1.03 (0.85–1.25) 0.74 1.10 (0.82–1.46) 0.53 0.97 (0.69–1.37) 0.88 99.1
BL1_ht4 0.081 0.074 1.19 (0.82–1.72) 0.35 1.19 (0.82–1.72) 0.35 – – 71.3
BL2_ht1 0.461 0.455 1.03 (0.85–1.25) 0.76 1.13 (0.85–1.52) 0.40 0.93 (0.67–1.30) 0.69 99.2
BL3_ht3 0.062 0.055 1.12 (0.75–1.66) 0.59 1.19 (0.78–1.82) 0.41 0.27 (0.03–2.68) 0.27 59.8
BL4_ht3 0.158 0.138 1.19 (0.91–1.56) 0.20 1.16 (0.86–1.56) 0.32 2.14 (0.72–6.34) 0.17 89.3
BL4_ht5 0.065 0.060 1.04 (0.71–1.54) 0.84 1.09 (0.72–1.63) 0.69 0.29 (0.03–3.29) 0.32 63.4
BL4_ht6 0.056 0.064 0.92 (0.62–1.38) 0.70 0.96 (0.63–1.44) 0.83 – – 56.3
BL5_ht2 0.370 0.389 0.93 (0.76–1.13) 0.44 1.01 (0.77–1.33) 0.94 0.73 (0.49–1.07) 0.10 98.8
BL5_ht3 0.121 0.112 1.09 (0.81–1.47) 0.57 1.09 (0.80–1.50) 0.59 1.21 (0.33–4.40) 0.77 85.1
BL6_ht2 0.265 0.253 1.08 (0.87–1.35) 0.48 1.09 (0.84–1.43) 0.51 1.13 (0.62–2.05) 0.69 97.8
BL6_ht3 0.125 0.116 1.09 (0.82–1.46) 0.55 1.11 (0.81–1.53) 0.50 0.94 (0.27–3.23) 0.92 86.1
BL7_ht2 0.205 0.241 0.81 (0.65–1.02) 0.07 0.94 (0.72–1.24) 0.68 0.28 (0.14–0.55) 0.0002 93.6
BL7_ht4 0.123 0.115 1.08 (0.81–1.45) 0.60 1.10 (0.80–1.51) 0.55 0.94 (0.27–3.23) 0.92 85.9
BL8_ht1 0.467 0.466 1.02 (0.85–1.22) 0.85 0.91 (0.68–1.21) 0.51 1.18 (0.86–1.61) 0.31 99.3
BL10_ht2 0.341 0.356 0.92 (0.76–1.12) 0.41 0.83 (0.63–1.08) 0.16 1.09 (0.73–1.64) 0.68 98.8
BL11_ht2 0.288 0.319 0.85 (0.69–1.04) 0.12 0.82 (0.63–1.06) 0.13 0.81 (0.51–1.30) 0.38 97.5
Open in a new tab

Notes: Boldface indicates P-value <0.05. P-values of GWAS represent the codominant model, which includes the additive model, adjusted for age and sex as covariates.

*

P-value of logistic analysis under additive model by adjusting for sex and age as covariates.

Abbreviations: AA, amino acid; AL, alcoholic subjects; GWAS, genome-wide association study; ht, haplotype; MAF, minor allele frequency; PRMT8, protein arginine methyltransferase.

Table S2.

Association analysis of PRMT8 SNPs with the AUDIT score in all study subjects (n=914)

Category Loci C/C
C/R
R/R
P-value*
N AUDIT score N AUDIT score N AUDIT score
AUDIT all rs4766138 572 18.77±11.79 296 18.20±11.81 46 12.65±12.10 0.01
rs4766139 562 18.75±11.79 303 18.36±11.82 49 12.33±11.80 0.01
rs12581829 711 18.81±11.76 183 16.34±12.01 19 16.21±13.06 0.008
Alcohol consumption rs4766138 572 8.12±3.58 296 7.98±3.61 46 6.48±4.25 0.04
rs4766139 562 8.12±3.58 303 8.01±3.61 49 6.43±4.13 0.03
rs12581829 711 8.13±3.56 183 7.45±3.88 19 7.74±3.86 0.03
Alcohol dependence rs4766138 572 4.31±4.10 296 4.21±4.02 46 2.74±3.87 0.08
rs4766139 562 4.28±4.09 303 4.30±4.05 49 2.59±3.80 0.09
rs12581829 711 4.30±4.08 183 3.83±4.03 19 3.53±4.36 0.09
Alcohol-related harm rs4766138 572 6.34±5.22 296 6.02±5.21 46 3.43±4.96 0.005
rs4766139 562 6.35±5.23 303 6.06±5.20 49 3.31±4.86 0.003
rs12581829 711 6.38±5.23 183 5.07±5.11 19 4.95±5.71 0.001
Open in a new tab

Notes: C/C, C/R, and R/R mean major homozygote, heterozygote, and minor homozygote, respectively. AUDIT score is mean±SD.

*

P-value of linear regression analysis under additive model by adjusting for sex and age as covariates. Boldface indicates P-value <0.05.

Abbreviations: AUDIT, Alcohol Use Disorders Identification Test; PRMT8, protein arginine methyltransferase.

Articles from Neuropsychiatric Disease and Treatment are provided here courtesy of Dove Press

RESOURCES